Neutral summary of Mochi Health’s advertised compounded GLP-1 program and membership structure, from secondary comparison data, not confirmed against the live site this cycle.
As of publication, GLP-1 Review Board has not established a referral relationship with Mochi Health. See our affiliate disclosure. Compensation, if any, would not affect this review or Mochi Health’s position in any list.
Provider data may change · advertised price · last checked 2026-06-25 · availability may vary by state and prescribing basis.
| Component | Reported price | Effective | Provenance |
|---|---|---|---|
| Base membership | ~$79/mo | ~$278 | secondary / not re-verified |
| Tirzepatide add-on | ~$199/mo |
Reported as membership-plus-add-on with bundled programming. Not confirmed on the live site this cycle.
• Membership: ~$79/mo required, separate from medication (secondary).
• Shipping/dose pricing: verify directly.
• Compare effective monthly total against flat-price providers, not the add-on alone.
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list (comment closed Jun 29, 2026). Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.
Secondary sources indicate a 503A pharmacy partner not named publicly — a transparency gap. Ask which pharmacy fills, its accreditation, and whether testing results are available.
Secondary sources report ~10 states (e.g. AZ, CO, FL, GA, IL, MA, MD, MN, NY, OR). Not confirmed against the live site.
Availability may vary by state and prescribing basis; not independently confirmed state by state. Verify directly before enrolling.
We have not verified Mochi’s cancellation/refund terms, including how membership and add-on are billed separately. Review current terms directly.
• “Structured programming / coaching.” Provider-stated (secondary); weigh against the higher effective price.
• Any “same as branded” or “generic” framing would be a red flag per our safety guidance.
No. Compounded tirzepatide and semaglutide are not FDA-approved and are not the same as branded products.
It combines a base membership with a medication add-on and bundles programming. Compare effective monthly totals; the extra cost buys services, not a different drug.
Update history. 2026-06 — initial profile from secondary data; live verification pending; no referral relationship at publication.